Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial

(2020) Sofia Pazmino et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA

(2019) Veerle Stouten et al.   RHEUMATOLOGY

What is the best treatment for early rheumatoid arthritis?

(2019) Janet E Pope   RHEUMATOLOGY

Diagnosis and Management of Rheumatoid Arthritis

(2018) Daniel Aletaha et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial

(2017) Nicole P. C. Konijn et al.   RHEUMATOLOGY

The use of glucocorticoids in early rheumatoid arthritis

(2017) Patrick Verschueren et al.   RHEUMATOLOGY

Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment

(2016) Iris M. Markusse et al.   ANNALS OF INTERNAL MEDICINE

Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial

(2016) Patrick Verschueren et al.   ANNALS OF THE RHEUMATIC DISEASES

Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial

(2015) Patrick Verschueren et al.   ARTHRITIS RESEARCH & THERAPY

Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial

(2014) Marieke M ter Wee et al.   ANNALS OF THE RHEUMATIC DISEASES

Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial

(2014) P Verschueren et al.   ANNALS OF THE RHEUMATIC DISEASES

What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review

(2013) J A B van Nies et al.   ANNALS OF THE RHEUMATIC DISEASES

Multiple Imputation for Missing Data via Sequential Regression Trees

(2010) L. F. Burgette et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis

(2009) L. H. D. van Tuyl et al.   ANNALS OF THE RHEUMATIC DISEASES

Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis

(2007) P. Verschueren et al.   RHEUMATOLOGY